Avigan effectiveness not yet clear, Japan health ministry panel says Sorry, but your browser needs Javascript to use this site. If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
Jiji Dec 22, 2020
A health ministry panel has postponed a decision on whether to approve the use of influenza drug Avigan as a treatment for COVID-19, citing difficulty in determining the drug’s effectiveness with currently available data.
The Pharmaceutical Affairs and Food Sanitation Council will examine Avigan’s effectiveness again early next year, or later, if Fujifilm Toyama Chemical Co., a Fujifilm Holdings Corp. subsidiary that developed the drug, submits additional data from its ongoing clinical tests.